One of the highlights of Eli Lilly's third-quarter results ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus ...

Eli Lilly has called on financial regulators ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...

An example is at Google. Anat Ashkenazi, the former CFO of Eli Lilly and Company, became the CFO of Google and Alphabet on July 31. Ashkenazi succeeded Ruth Porat who was CFO for almost 10 years.

today announced that Anat Ashkenazi, currently Executive Vice President and Chief Financial... Eli Lilly and Company (NYSE:LLY) announced today that Anat Ashkenazi has resigned as chief financial ...

It is also a huge week for biotech and pharmaceutical earnings, with Amgen, Pfizer, Eli Lilly and Neurocrine ... Alphabet's new chief financial officer, Anat Ashkenazi, is expected to lay out ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief... San Francisco, June 5 (IANS) Google (NASDAQ:GOOGL) parent Alphabet ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its rival pharmaceutical companies Eli Lilly’s stock surged 16% after the ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.